ABVIRO LLC
BETHESDA, MARYLAND 208142934
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541715 | $8.74M | 7 |
| 541711 | $-379,044.77 | 7 |
Contract Awards
8 awards found
THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.
THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.
TO CONDUCT A PHASE 2 DENGUE HUMAN CHALLENGE CLINICAL TRIAL OF ABVIRO ANTI-DENGUE MONOCLONAL ANTIBODY (MAB) AV-1.
THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.
THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.
Business Details
- UEI
- K3L6KXJ9B6M7
- CAGE Code
- 75YF3
- Address
- 4800 HAMPDEN LN STE 200
BETHESDA, MD 208142934 - Congressional District
- MD-08
- Phone
- 2022863229
Parent Company
ABVIRO LLC
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov